Pasithea Therapeutics Files 8-K
Ticker: KTTAW · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1841330
Sentiment: neutral
Topics: 8-K, financial-statements, regulation-fd
TL;DR
Pasithea Therapeutics filed an 8-K on 9/26/24 for Reg FD and financials.
AI Summary
Pasithea Therapeutics Corp. filed an 8-K on September 26, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing indicates the company's principal executive office is located at 1111 Lincoln Road, Suite 500, Miami Beach, Florida, 33139.
Why It Matters
This 8-K filing provides updates on Pasithea Therapeutics Corp.'s regulatory disclosures and financial statements, which are important for investors to understand the company's current status.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial statements and regulatory information, not indicating any immediate operational or financial distress.
Key Players & Entities
- Pasithea Therapeutics Corp. (company) — Registrant
- September 26, 2024 (date) — Date of earliest event reported
- 1111 Lincoln Road , Suite 500 Miami Beach , Florida 33139 (address) — Principal executive office
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 26, 2024.
What is the state of incorporation for Pasithea Therapeutics Corp.?
Pasithea Therapeutics Corp. is incorporated in Delaware.
What is the IRS Employer Identification Number for Pasithea Therapeutics Corp.?
The IRS Employer Identification Number for Pasithea Therapeutics Corp. is 85-1591963.
Where is Pasithea Therapeutics Corp.'s principal executive office located?
Pasithea Therapeutics Corp.'s principal executive office is located at 1111 Lincoln Road, Suite 500, Miami Beach, Florida, 33139.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-09-26 08:45:07
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share KTTA The Nasdaq Capital M
Filing Documents
- ea0215731-8k_pasithea.htm (8-K) — 28KB
- ea021573101ex99-1_pasithea.htm (EX-99.1) — 25KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- ex99-1_002.jpg (GRAPHIC) — 14KB
- 0001213900-24-081982.txt ( ) — 304KB
- ktta-20240926.xsd (EX-101.SCH) — 4KB
- ktta-20240926_def.xml (EX-101.DEF) — 26KB
- ktta-20240926_lab.xml (EX-101.LAB) — 36KB
- ktta-20240926_pre.xml (EX-101.PRE) — 25KB
- ea0215731-8k_pasithea_htm.xml (XML) — 6KB
01 Regulation FD
Item 7.01 Regulation FD. On September 26, 2024, Pasithea Therapeutics Corp. issued a press release announcing positive initial safety, tolerability, pharmacokinetic, and preliminary efficacy data from its Phase 1 clinical trial of PAS-004 in advanced cancer. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 26, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASITHEA THERAPEUTICS CORP. Date: September 26, 2024 By: /s/ Tiago Reis Marques Name: Tiago Reis Marques Title: Chief Executive Officer 2